CytoMed Therapeutics (GDTC) Competitors $1.68 -0.07 (-4.00%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock GDTC vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. CytoMed Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity 180 Life Sciences (NASDAQ:ATNFW) and CytoMed Therapeutics (NASDAQ:GDTC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Does the media favor ATNFW or GDTC? In the previous week, 180 Life Sciences had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 4 mentions for 180 Life Sciences and 2 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.43 beat 180 Life Sciences' score of 0.98 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Positive CytoMed Therapeutics Positive Do analysts recommend ATNFW or GDTC? CytoMed Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 182.49%. Given CytoMed Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytoMed Therapeutics is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, ATNFW or GDTC? 180 Life Sciences has higher earnings, but lower revenue than CytoMed Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ACytoMed Therapeutics$50KN/A-$1.84MN/AN/A Is ATNFW or GDTC more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A CytoMed Therapeutics N/A N/A N/A Do insiders and institutionals have more ownership in ATNFW or GDTC? 0.0% of CytoMed Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryCytoMed Therapeutics beats 180 Life Sciences on 6 of the 7 factors compared between the two stocks. Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDTC vs. The Competition Export to ExcelMetricCytoMed TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2925.74Price / SalesN/A356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book2.908.608.826.15Net Income-$1.84M-$54.65M$3.25B$265.06M7 Day Performance-4.32%5.43%4.05%2.80%1 Month Performance-19.91%6.75%4.32%1.68%1 Year Performance5.36%31.59%36.25%29.59% CytoMed Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDTCCytoMed Therapeutics2.6508 of 5 stars$1.77+1.1%$5.00+182.5%+2.3%$0.00$50K0.00N/APositive NewsShort Interest ↓ATNFW180 Life SciencesN/A$0.01-0.9%N/A+6,690.1%$0.00N/A0.007News CoverageLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01+84.9%N/AN/A$0.00N/A0.002Gap DownAIMDWAinosN/A$0.11-8.3%N/AN/A$0.00$106.21K0.0040Gap UpALVOWAlvotechN/A$1.60-17.5%N/A-47.5%$0.00$585.60M0.004Gap DownACABWAtlantic Coastal Acquisition Corp. IIN/A$0.05+2.9%N/A-62.3%$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.15-2.6%N/AN/A$0.00$38.00M0.0070Gap DownBTMDWbioteN/A$0.02+19.3%N/A-97.8%$0.00$199.38M0.00N/AGap UpBCTXWBriaCell TherapeuticsN/A$0.03-12.0%N/A-86.3%$0.00N/A0.008Short Interest ↓Gap DownCELUWCelularityN/A$0.05-10.0%N/AN/A$0.00$54.22M0.00220News CoveragePositive NewsGap Down Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors CELUW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GDTC) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access